CG Oncology Completes Enrollment in PIVOT-006 Study for Intermediate-Risk NMIBC

CG Oncology has completed enrollment in its Phase 3 PIVOT-006 study comparing adjuvant intravesical cretostimogene grenadenorepvec versus surveillance in patients with intermediate-risk non-muscle invasive bladder cancer. Cretostimogene is an investigational oncolytic immunotherapy candidate that has been studied in a clinical development program including over 400 patients with NMIBC. The company also has a Phase 2 trial, CORE-008, evaluating cretostimogene in high-risk NMIBC.